

## Prof. Senem KARABULUT

### Personal Information

Office Phone: [+90 212 414 2400](tel:+902124142400)

Email: [senem.karabulut@istanbul.edu.tr](mailto:senem.karabulut@istanbul.edu.tr)

Web: <https://avesis.istanbul.edu.tr/senem.karabulut>

### International Researcher IDs

ORCID: 0000-0003-4740-9973

Publons / Web Of Science ResearcherID: AAT-3594-2020

Yoksis Researcher ID: 259185

### Education Information

Doctorate, University Of Health Sciences, Sağlık Meslek Yüksek Okulu, Moleküler Onkoloji, Turkey 2018 - 2023

Post Doctorate of Medicine, Istanbul University, Istanbul Medical Faculty, Division Of Medical Sciences , Turkey 2011 - 2015

Expertise In Medicine, Diğer (Kurumlar,hastaneler Vb.), FATİH SULTAN MEHMET EĞİTİM ARAŞTIRMA HASTANESİ, Turkey 2004 - 2010

Undergraduate, Istanbul University, Istanbul Medical Faculty, Turkey 1996 - 2003

### Foreign Languages

English, C1 Advanced

### Dissertations

Doctorate, Kolorektal Kanserli Hastaların Kan Örneklerinde Let-7, miRNA125b ve miRNA30a Seviyelerinin Araştırılması, Istanbul University, Istanbul Medical Faculty, Division Of Medical Sciences , 2022

Post Doctorate of Medicine, Meme kanserli kadınlarda hücrel adhezyon moleküllerinin prognostik ve prediktif değerinin araştırılması, Istanbul University, Istanbul Medical Faculty, Division Of Medical Sciences , 2014

Expertise In Medicine, Türk toplumunda organik ve fonksiyonel dispepsili hastalarda etyolojiye yönelik analiz, Diğer (Kurumlar,hastaneler Vb.), 2010

### Research Areas

Oncology

### Academic Titles / Tasks

Professor, Istanbul University, Istanbul Medical Faculty, Division Of Medical Sciences , 2023 - Continues

Associate Professor, Istanbul University, Istanbul Medical Faculty, Division Of Medical Sciences , 2018 - 2023

Expert PhD, University Of Health Sciences, Bakırköy Dr Sadi Konuk Eğitim ve Araştırma Hastanesi, Tıbbi Onkoloji Kliniği, 2015 - 2018

## Courses

Kanser kinetiği ve kemoterapi prensipleri , Undergraduate, 2022 - 2023, 2021 - 2022, 2020 - 2021, 2019 - 2020, 2018 - 2019  
Primeri Bilinmeyen Kansere Yaklaşım , Undergraduate, 2022 - 2023, 2021 - 2022, 2020 - 2021, 2019 - 2020  
Tıbbi Onkoloji, Expertise In Medicine, 2017 - 2018, 2016 - 2017, 2015 - 2016  
Temel Onkoloji , Associate Degree, 2015 - 2016  
Radyasyon Onkolojisi , Associate Degree, 2015 - 2016

## Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer**  
Tasci E. S., Oyan B., Soenmez O., Mutlu A. U., Atci M. M., Sakin A., Oener I., Cinkir H. Y., Eryilmaz M. K., Caglayan D., et al.  
BMC CANCER, vol.24, no.1, 2024 (SCI-Expanded)
- II. **Is there any diagnostic value of serum caveolin-1 levels on the determination of pancreatic adenocarcinoma?**  
Karabulut S., Afsar C. U., Paksoy N., Ferhatoglu F., Dogan I., Tastekin D.  
Journal of cancer research and therapeutics, 2024 (SCI-Expanded)
- III. **Disease characteristics and prognostic factors of colorectal cancer patients with bone metastasis: A real-world data from Turkey.**  
Karabulut S., Afsar C. U., Khanmammadov N., Karahan L., Paksoy N., Dogan I., Ferhatoglu F., Tastekin D.  
Journal of cancer research and therapeutics, 2024 (SCI-Expanded)
- IV. **Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.**  
Karabulut S.  
BMC CANCER, vol.24, no.1, pp.114, 2024 (SCI-Expanded)
- V. **The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing**  
KÖSTEK O., Demirel A., Hacıoğlu M. B., TAŞTEKİN D., KARABULUT S., Gündoğdu A., Sever N., Ayhan M., Çelebi A., Majidova N., et al.  
Journal of Chemotherapy, 2024 (SCI-Expanded)
- VI. **Investigation of the potential of miRNA candidates as non-invasive biomarkers for the diagnosis and follow-up of colorectal cancer**  
Karabulut S., Şen S., Oğuz Soydu H., Doğan I., Taştekin D., Karabulut M., Duman M., Turan M.  
Pathology - Research and Practice, vol.254, pp.1-7, 2024 (SCI-Expanded)
- VII. **Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group**  
Ünal Ç., AZİZY A., KARABULUT S., TAŞTEKİN D., AKYILDIZ A., YAŞAR S., YALÇIN Ş., Çoban E., EVRENSEL T., Kalkan Z., et al.  
The oncologist, vol.28, no.10, pp.875-884, 2023 (SCI-Expanded)
- VIII. **SERUM FETUIN-A AND RANKL LEVELS IN PATIENTS WITH EARLY STAGE BREAST CANCER SERUM FETUIN-A I NIVOI RANKLA KOD PACIJENATA SA RANIM STADIJOM RAKA DOJKE**  
Afsar C. U., Aral H., Can O., Trabulus D. C., Karacetin D., Nazlı M. A., Gursu R. U., KARABULUT S.  
Journal of Medical Biochemistry, vol.42, no.2, pp.249-257, 2023 (SCI-Expanded)
- IX. **Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first-line treatment of metastatic gastric cancer: A single-center experience**  
TAŞTEKİN D., Paksoy N., DOĞAN İ., Ferhatoglu F., KHANMAMMADOV N., Bozbey H. U., KARABULUT S.  
Journal of cancer research and therapeutics, vol.19, no.2, pp.253-258, 2023 (SCI-Expanded)

- X. **Prognostic value of FDG PET-CT in suspected recurrence of colorectal carcinoma: survival outcomes of a 10-year follow-up : FDG PET in recurrent colorectal CA.**  
ozkan Z. G., Has Simsek D., Kuyumcu S., Oflas M., Isik E. G., Dogan I., Karabulut S., Sanli Y.  
Annals of nuclear medicine, vol.36, no.1, pp.52-60, 2022 (SCI-Expanded)
- XI. **Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)**  
Erol C., Sakin A., Bařoglu T., Özden E., ÇABUK D., Dođan M., Öksüzođlu B., YILDIRIM H. Ç., Öner İ., Karakurt Eryilmaz M., et al.  
Turkish Journal of Medical Sciences, vol.52, no.4, pp.1022-1032, 2022 (SCI-Expanded)
- XII. **Does nutritional status affect treatment tolerability, response and survival in metastatic colorectal cancer patients? Results of a prospective multicenter study**  
Karabulut S., Dogan I., Usul Afsar C., Karabulut M., Karaman S., Ferhatoglu F., Tastekin D.  
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.27, no.6, pp.1357-1363, 2021 (SCI-Expanded)
- XIII. **CLINICAL UTILITY OF TENSIN 2 LEVELS AS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER IN BREAST CANCER**  
SERİN K. R., Ucuncu Z., TEMEL M. K., BADEMLER S., Soydinc H. O., KARANLIK H., KARABULUT S.  
ACTA MEDICA MEDITERRANEA, vol.37, no.1, pp.553-558, 2021 (SCI-Expanded)
- XIV. **A retrospective multicenter study: Clinicopathological factors affecting recurrence-free survival in operable gastric cancer patients.**  
Yekeduz E., Dogan I., AKBULUT H., Karabulut S., Utkan G., ÜRÜN Y.  
JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.3, 2021 (SCI-Expanded)
- XV. **Temozolomide and capecitabine (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors.**  
Dogan I., Tastekin D., Karabulut S., Sakar B.  
JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.3, 2021 (SCI-Expanded)
- XVI. **Circulating annexin A2 as a biomarker in patients with pancreatic cancer.**  
Karabulut M., Afsar C. U., Serilmez M., Karabulut S.  
Journal of cancer research and therapeutics, vol.16, 2020 (SCI-Expanded)
- XVII. **Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey**  
Hacioglu M. B., Kostek O., Karabulut S., Tastekin D., SEZGİN GÖKSU S., Alandag C., Akagunduz B., Bilgetekin I., Caner B., ŞAHİN A. B., et al.  
JOURNAL OF BUON, vol.25, no.4, pp.1897-1903, 2020 (SCI-Expanded)
- XVIII. **Comparison of serum NEDD-9, CA 15-3, and CEA levels and PET metabolic parameters in breast cancer patients with 18 F-FDG PET / CT**  
Arslan E., Aral H., Aksoy T., Afsar C. U., Karabulut S., Trabulus F. D. C., Gursu R. U., Cermik T. F.  
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, vol.66, no.5, pp.673-679, 2020 (SCI-Expanded)
- XIX. **The Diagnostic Significance of PDGF, EphA7, CCR5, and CCL5 Levels in Colorectal Cancer**  
Ucuncu M., Serilmez M., Sari M., Bademler S., Karabulut S.  
BIOMOLECULES, vol.9, no.9, 2019 (SCI-Expanded)
- XX. **Serum IL-17 levels can be diagnostic for gastric cancer.**  
Karabulut M., Afsar C. U., Serimez M., Karabulut S.  
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.24, no.4, pp.1601-1609, 2019 (SCI-Expanded)
- XXI. **Serum IL-17 levels can be diagnostic for gastric cancer**  
Karabulut M., Usul Afsar Ç., Serilmez M., Karabulut S.  
Journal Of Buon, vol.24, no.4, pp.1-9, 2019 (SCI-Expanded)
- XXII. **Clinical significance of serum membrane-bound mucin-2 levels in breast cancer**  
Bademler S., ZİRTİLOĞLU A., Sari M., Ucuncu M. Z., Dogru E., Karabulut S.  
Biomolecules, vol.9, no.2, 2019 (SCI-Expanded)
- XXIII. **IGF-1 AND IGFBP-3 IN COLORECTAL CANCER, AN OBSERVATIONAL CASE-CONTROL STUDY**

- Bademler S, ZİRTİLOĞLU A., Sari M., Yasasever C., Karabulut S.  
ACTA MEDICA MEDITERRANEA, vol.35, no.1, pp.15-21, 2019 (SCI-Expanded)
- XXIV. **Clinical significance of serum caveolin-1 levels in gastric cancer patients.**  
Tas F., Karabulut S., Erturk K., Duranyildiz D.  
Experimental oncology, vol.40, pp.323-327, 2018 (SCI-Expanded)
- XXV. **Clinical Significance of Serum NEDD9 Levels in Patients with Pancreatic Cancer**  
Afsar C. U., Karabulut M., Karabulut S., Ozal S. T., Cikot M., Serilmez M., Tas F.  
BIOMOLECULES, vol.8, no.4, 2018 (SCI-Expanded)
- XXVI. **Kras-mutation influences outcomes for palliative primary tumor resection in advanced colorectal cancer-a Turkish Oncology Group study**  
Korkmaz L., COŞKUN H. Ş., DANE F., KARABULUT B., Karaagac M., ÇABUK D., Karabulut S., Aykan N. F., Doruk H., Avcı N., et al.  
SURGICAL ONCOLOGY-OXFORD, vol.27, no.3, pp.485-489, 2018 (SCI-Expanded)
- XXVII. **Clinical significance of serum leptin level in patients with gastric cancer**  
Tas F., Karabulut S., Erturk K., Duranyildiz D.  
EUROPEAN CYTOKINE NETWORK, vol.29, no.2, pp.52-58, 2018 (SCI-Expanded)
- XXVIII. **Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth binding protein-3 (IGFBP-3) in patients with gastric cancer**  
BADEMLER S., Sari M., Üçüncü M. Z., SERİLMEZ M., Karabulut S.  
Acta Medica Mediterranea, vol.34, no.6, pp.2055-2060, 2018 (SCI-Expanded)
- XXIX. **Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma**  
Afsar C. U., Karabulut M., Karabulut S., Alis H., Gonenc M., Dagoglu N., Serilmez M., Tas F.  
JOURNAL OF INFECTION AND CHEMOTHERAPY, vol.23, pp.196-200, 2017 (SCI-Expanded)
- XXX. **Assessment of Anxiety and Depression Status in Turkish Cutaneous Melanoma Patients**  
Tas F., Karabulut S., Guveli H., Kurul S., Erturk K., Guveli M., Kinik H.  
Asian Pacific journal of cancer prevention : APJCP, vol.18, pp.369-373, 2017 (SCI-Expanded)
- XXXI. **SERUM INTERLEUKIN-32 (IL-32) LEVELS MAY HAVE DIAGNOSTIC AND PROGNOSTIC ROLES IN PATIENTS WITH PANCREATIC ADENOCARCINOMA**  
Karabulut M., Afsar C. U., Karabulut S., Peker K. D., Gemici E., Dagoglu N., Karaman S., Yasasever C. T., Tas F.  
ACTA MEDICA MEDITERRANEA, vol.33, no.4, pp.613-619, 2017 (SCI-Expanded)
- XXXII. **THE EFFECT OF PRETREATMENT NEUTROPHIL/LEUCOCYTE RATIO ON SURVIVAL IN PATIENTS WITH LOCALLY ADVANCED ESOPHAGEAL CANCER RECEIVING CHEMORADIOTHERAPY**  
Karaca F., Afsar C. U., Almalı N., KARABULUT S., Karabulut M., Keskin S., AKBULUT S.  
ACTA MEDICA MEDITERRANEA, vol.33, no.6, pp.905-911, 2017 (SCI-Expanded)
- XXXIII. **CIRCULATING MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1/CCL-2) AS A POTENTIAL BIOMARKER FOR THE DIAGNOSIS OF PANCREATIC ADENOCARCINOMA**  
Afsar C. U., Karabulut M., Karabulut S., Alis H., Binboga S., Bilgin E., Aykan N. F.  
ACTA MEDICA MEDITERRANEA, vol.33, no.3, pp.501-507, 2017 (SCI-Expanded)
- XXXIV. **Clinical significance of serum interleukin-17 levels in colorectal cancer patients**  
Karabulut S., Afsar C. U., Karabulut M., Kilic L., Alis H., Kones O., Bilgin E., Aykan N. F.  
JOURNAL OF BUON, vol.21, no.5, pp.1137-1145, 2016 (SCI-Expanded)
- XXXV. **Serum leptin levels may have diagnostic and predictive roles in patients with pancreatic adenocarcinoma treated with gemcitabine-based chemotherapy.**  
Karabulut S., AFSAR C. U., KARABULUT M., ALIS H., Erturk K., Karaman S., KONES O., Bilgin E., Tas F.  
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.21, no.4, pp.895-902, 2016 (SCI-Expanded)
- XXXVI. **Clinical significance of serum caveolin-1 levels in melanoma patients**  
Tas F., Karabulut S., Yasasever C. T., Duranyildiz D.  
INTERNATIONAL JOURNAL OF DERMATOLOGY, vol.55, no.5, pp.558-562, 2016 (SCI-Expanded)
- XXXVII. **Serum nectin-2 levels are diagnostic and prognostic in patients with colorectal carcinoma.**  
KARABULUT M., GUNALDI M., ALIS H., AFSAR C., KARABULUT S., Serilmez M., AKARSU C., SEYIT H., AYKAN N. F.

- Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol.18, pp.160-71, 2016 (SCI-Expanded)
- XXXVIII. **Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer**  
Tas F., Karabulut S., Serilmez M., KARABULUT M., Duranyildiz D.  
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.77, no.1, pp.127-131, 2016 (SCI-Expanded)
- XXXIX. **Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutation**  
ERDOĞAN B., Kodaz H., Karabulut S., Cinkaya A., TOZKIR H., TANRIVERDİ Ö., ÇABUK D., Hacıoğlu M. B., Turkmen E., Hacibekiroğlu I., et al.  
BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, vol.16, no.4, pp.280-285, 2016 (SCI-Expanded)
- XL. **CIRCULATING MACROPHAGE INFLAMMATORY PROTEIN-1 ALPHA (MIP1-A) AS A POTENTIAL BIOMARKER FOR THE DIAGNOSIS OF PATIENTS WITH PANCREATIC ADENOCARCINOMA**  
Karabulut S., Afsar C. U., Karabulut M., Alis H., Binboga S., Ozkara I. O., Karaca F., Bilgin E., Tas F.  
ACTA MEDICA MEDITERRANEA, vol.32, no.4, pp.1035-1040, 2016 (SCI-Expanded)
- XLI. **CLINICAL SIGNIFICANCE OF SERUM HEPATOCYTE GROWTH FACTOR (HGF) AND ITS RECEPTOR CMET LEVELS IN COLORECTAL CANCER PATIENTS**  
KARABULUT M., ALIS H., GUNALDI M., AFSAR C. U., Karabulut S., KONES O., SEYIT H., Serilmez M., Aykan N. F.  
ACTA MEDICA MEDITERRANEA, vol.32, no.1, pp.179-187, 2016 (SCI-Expanded)
- XLII. **Pankreas Adenokanserli Hastalarda Serum Ekstrasellüler Matriks Proteinlerinin Prognostik ve Prediktif Değerinin Araştırılması**  
KARABULUT S., KARABULUT M., ALIS H., DAĞOĞLU N., TAMBAŞ M., KAPA S., ORAN E., OĞUZ SOYDİNÇ H., TAŞ F.  
Bakırköy Tıp Dergisi, vol.12, no.1, pp.24-32, 2016 (SCI-Expanded)
- XLIII. **Serum neural precursor cell-expressed, developmentally down regulated 9 (NEDD9) level may have a prognostic role in patients with gastric cancer**  
KARABULUT M., ALIS H., AFSAR C. U., Karabulut S., KOCATAS A., Oguz H., Aykan N. F.  
BIOMEDICINE & PHARMACOTHERAPY, vol.73, pp.140-146, 2015 (SCI-Expanded)
- XLIV. **Tongue metastasis of melanoma**  
Tas F., Karabulut S., Yegen G., Onder S., Ciftci R.  
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.11, no.3, 2015 (SCI-Expanded)
- XLV. **Clinical significance of serum interleukin-18 (IL-18) levels in patients with gastric cancer**  
Tas F., Yasasever C. T., Karabulut S., Tastekin D., Duranyildiz D.  
BIOMEDICINE & PHARMACOTHERAPY, vol.70, pp.19-23, 2015 (SCI-Expanded)
- XLVI. **Serum transforming growth factor-beta1 levels may have predictive and prognostic roles in patients with gastric cancer.**  
Tas F., Yasasever C. T., Karabulut S., Tastekin D., Duranyildiz D.  
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, vol.36, no.3, pp.2097-103, 2015 (SCI-Expanded)
- XLVII. **Clinical significance of serum epidermal growth factor receptor (EGFR) levels in patients with breast cancer**  
Tas F., Bilgin E., Karabulut S., Duranyildiz D.  
CYTOKINE, vol.71, no.1, pp.66-70, 2015 (SCI-Expanded)
- XLVIII. **Combination of Capecitabine and Phenytoin May Cause Phenytoin Intoxication: A Case Report**  
Ciftci R., Tas F., Karabulut S., CIFTCI S.  
AMERICAN JOURNAL OF THERAPEUTICS, vol.22, no.1, 2015 (SCI-Expanded)
- XLIX. **D-dimer and international normalized ratio (INR) are correlated with tumor markers and disease stage in colorectal cancer patients.**  
Kilic L., Yildiz I., Sen F. K., ERDEM M. G., Serilmez M., Keskin S., Ciftci R., Karabulut S., ORDU C., Duranyildiz D., et al.  
Cancer biomarkers : section A of Disease markers, vol.15, no.4, pp.405-11, 2015 (SCI-Expanded)
- L. **Circulating annexin A2 as a biomarker in gastric cancer patients: Correlation with clinical variables**

Tas F., Yasasever C. T., Karabulut S., Tastekin D., Duranyildiz D.

Biomedicine and Pharmacotherapy, vol.69, pp.237-241, 2015 (SCI-Expanded)

- L.I. **Clinical significance of serum epithelial cell adhesion molecule (EPCAM) levels in patients with lung cancer**  
Tas F., Karabulut S., Duranyildiz D.  
MOLECULAR AND CELLULAR BIOCHEMISTRY, vol.396, pp.307-312, 2014 (SCI-Expanded)
- L.II. **Clinical significance of serum M30 and M65 levels in patients with breast cancer**  
Tas F., Karabulut S., Yildiz I., Duranyildiz D.  
BIOMEDICINE & PHARMACOTHERAPY, vol.68, no.8, pp.1135-1140, 2014 (SCI-Expanded)
- L.III. **Clinical significance of serum fibronectin and vitronectin levels in melanoma patients**  
Tas F., Karabulut S., Bilgin E., Tastekin D., Duranyildiz D.  
MELANOMA RESEARCH, vol.24, no.5, pp.475-479, 2014 (SCI-Expanded)
- L.IV. **Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) in patients with breast cancer**  
Tas F., Karabulut S., Bilgin E., Tastekin D., Duranyildiz D.  
TUMOR BIOLOGY, vol.35, no.9, pp.9303-9309, 2014 (SCI-Expanded)
- L.V. **The Behavior of Turkish Cancer Patients in Fasting During the Holy Month of Ramadan**  
Tas F., Karabulut S., Ciftci R., Yildiz I., Keskin S., Kilic L., Disci R.  
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, vol.44, no.8, pp.705-710, 2014 (SCI-Expanded)
- L.VI. **Serum levels of vascular cell adhesion molecule-1 (VCAM-1) may have diagnostic, predictive, and prognostic roles in patients with lung cancer treated with platinum-based chemotherapy**  
Tas F., Karabulut S., Bilgin E., Duranyildiz D.  
TUMOR BIOLOGY, vol.35, no.8, pp.7871-7875, 2014 (SCI-Expanded)
- L.VII. **Serum transforming growth factor-beta 1 (TGF-beta 1) levels have diagnostic, predictive, and possible prognostic roles in patients with melanoma**  
Tas F., Karabulut S., Yasasever C., Duranyildiz D.  
TUMOR BIOLOGY, vol.35, no.7, pp.7233-7237, 2014 (SCI-Expanded)
- L.VIII. **Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy**  
Tas F., Karabulut S., Ciftci R., Sen F., Sakar B., Disci R., Duranyildiz D.  
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.73, no.6, pp.1163-1171, 2014 (SCI-Expanded)
- L.IX. **Clinical significance of serum ADP-ribosylation and NAD glycohydrolase activity in patients with colorectal cancer.**  
Varol B., ÇOŞKUN Ö., Karabulut S., SERIN K. R., Asoglu O., Albeniz I., Tas F., Nurten R.  
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, vol.35, no.6, pp.5575-82, 2014 (SCI-Expanded)
- L.X. **Clinical significance of serum transforming growth factor-beta 1 (TGF-beta 1) levels in patients with epithelial ovarian cancer**  
Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.  
TUMOR BIOLOGY, vol.35, no.4, pp.3611-3616, 2014 (SCI-Expanded)
- L.XI. **Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer**  
Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.  
TUMOR BIOLOGY, vol.35, no.4, pp.3125-3132, 2014 (SCI-Expanded)
- L.XII. **Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in patients with epithelial ovarian cancer**  
Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.  
TUMOR BIOLOGY, vol.35, no.4, pp.3095-3102, 2014 (SCI-Expanded)
- L.XIII. **Serum levels of macrophage migration-inhibitory factor (MIF) have diagnostic, predictive and prognostic roles in epithelial ovarian cancer patients**  
Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.

- TUMOR BIOLOGY, vol.35, no.4, pp.3327-3331, 2014 (SCI-Expanded)
- LXIV. **Recurrent gastric cancer presenting with both scrotal and facial skin metastases: a case report.**  
Tas F, Ciftci R, Buyukbabani N, Karabulut S.  
Journal of gastrointestinal cancer, vol.45, pp.96-9, 2014 (SCI-Expanded)
- LXV. **Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer**  
Tas F, Karabulut S, Serilmez M, Ciftci R, Duranyildiz D.  
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.73, no.3, pp.631-637, 2014 (SCI-Expanded)
- LXVI. **High serum transforming growth factor beta 1 (TGFB1) level predicts better survival in breast cancer**  
Ciftci R, Tas F, Yasasever C, Aksit E, Karabulut S, Sen F, Keskin S, Kilic L, Yildiz I, Bozbey H. U., et al.  
Tumor Biology, vol.35, no.7, pp.6941-6948, 2014 (SCI-Expanded)
- LXVII. **Clinical significance of coagulation assays in metastatic pancreatic adenocarcinoma.**  
Tas F, Karabulut S, Bilgin E, Kilic L, Ciftci R, Duranyildiz D.  
Journal of gastrointestinal cancer, vol.44, pp.404-9, 2013 (SCI-Expanded)
- LXVIII. **Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma**  
Tas F, Karabulut S, Bilgin E, Sen F, Yildiz I, Tastekin D, Ciftci R, Duranyildiz D.  
TUMOR BIOLOGY, vol.34, no.6, pp.3529-3536, 2013 (SCI-Expanded)
- LXIX. **The role of surgical methods in the treatment of anorectal malignant melanoma (AMM).**  
Keskin S, Tas F, Karabulut S, Yildiz I, Kiliç L, Ciftci R, Vatansever S.  
Acta chirurgica Belgica, vol.113, pp.429-33, 2013 (SCI-Expanded)
- LXX. **Age is a prognostic factor affecting survival in lung cancer patients**  
Tas F, Ciftci R, Kilic L, Karabulut S.  
ONCOLOGY LETTERS, vol.6, no.5, pp.1507-1513, 2013 (SCI-Expanded)
- LXXI. **Clinical significance of serum M30 and M65 levels in melanoma**  
Tas F, Karabulut S, Serilmez M, Yildiz I, Sen F, Ciftci R, Duranyildiz D.  
MELANOMA RESEARCH, vol.23, no.5, pp.390-395, 2013 (SCI-Expanded)
- LXXII. **Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy**  
Aykan N. F., Yildiz I, Sen F, Kilic L, Keskin S, Ciftci R, Karabulut S, Sakar B, Disci R.  
MEDICAL ONCOLOGY, vol.30, no.3, 2013 (SCI-Expanded)
- LXXIII. **Clinical and prognostic significance of coagulation assays in gastric cancer.**  
Tas F, Ciftci R, Kilic L, Serilmez M, Karabulut S, Duranyildiz D.  
Journal of gastrointestinal cancer, vol.44, pp.285-92, 2013 (SCI-Expanded)
- LXXIV. **A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer**  
Yildiz I, Tas F, Kilic L, Sen F, Saip P, Eralp Y, Keskin S, Karabulut S, Ciftci R, Serilmez M., et al.  
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.72, no.2, pp.437-444, 2013 (SCI-Expanded)
- LXXV. **Biweekly triplet chemotherapy with gemcitabine, cisplatin and vinorelbine for advanced chemotherapy naïve non-small cell lung cancer.**  
Keskin S, Tas F, Ekenel M, Kilic L, Sen F, Yildiz I, Karabulut S, Ciftci R, Vatansever S.  
Tumori, vol.99, no.4, pp.463-8, 2013 (SCI-Expanded)
- LXXVI. **Does Beta-blocker Therapy Improve the Survival of Patients with Metastatic Non-small Cell Lung Cancer?**  
Aydiner A, Ciftci R, Karabulut S, Kilic L.  
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.14, no.10, pp.6109-6114, 2013 (SCI-Expanded)

## Articles Published in Other Journals

- I. **Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study**

Paksoy N., Ferhatoglu F., DOĞAN İ., Khanmammadov N., Bozbey H. U., KARABULUT S., Tastekin D.  
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.37, no.4, pp.478-483, 2022 (ESCI)

- II. **Recent Advances in Immunotherapy in the Treatment of Gastrointestinal Tract Cancers**  
Karabulut S., Topalgokceli M. S., Tastekin D.  
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, vol.6, no.1, pp.12-15, 2022 (ESCI)
- III. **WHAT'S NEW IN METASTATIC COLON CANCER TREATMENT?**  
Karabulut S., Karabulut M., Tastekin D.  
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGİSİ, vol.84, no.3, pp.425-429, 2021 (ESCI)
- IV. **Adjuvant Treatment of Gastric Cancer in the D2 Dissection Era: A Real-life Experience from a Multicenter Retrospective Cohort Study.**  
Yekedüz E., Doğan İ., Birgi S. D., Keskin M., Karaman Ş., Utkan G., Karabulut S., Bayar S., Akbulut H., Demirci S., et al.  
Euroasian journal of hepato-gastroenterology, vol.11, no.2, pp.51-58, 2021 (Peer-Reviewed Journal)
- V. **Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients**  
ARTAÇ M., Korkmaz L., COŞKUN H. Ş., DANE F., KARABULUT B., KARAAĞAÇ M., ÇABUK D., Karabulut S., Aykan N. F., Doruk H., et al.  
JOURNAL OF GASTROINTESTINAL CANCER, vol.50, no.2, pp.214-220, 2019 (ESCI)
- VI. **The Association of Pancreatic Cancer and PALB2 Gene Mutations in the Turkish Population**  
Turkcan G. K., Odemis D., Avsar M., Tuncer S. B., Erciyas S., Erdogan Ö., Tastekin D., Karabulut S., Kaytan E., Yazici H.  
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.34, no.4, pp.283-290, 2019 (ESCI)
- VII. **Serum Glypican-3, Vascular Endothelial Growth Factor, and Interleukin-6 Levels in Hepatocellular Carcinoma**  
Serilmez M., Akyuz F., Ormeci Ciftcibasi A., Karabulut S., Kaymakoglu S., Yasasever V., Duranyildiz D.  
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.33, no.1, pp.18-27, 2018 (ESCI)
- VIII. **Evaluation of epidermal growth factor receptor serum levels and their association with clinicopathological characteristics in patients with colorectal cancer.**  
KARABULUT M., AFSAR C., ALIŞ H., ORAN E., KARABULUT S., AKARSU C., SAHBAZ N. A., GÜMÜSOĞLU A. Y., Bilgin E., AYKAN N. F.  
Molecular and clinical oncology, vol.7, pp.787-797, 2017 (ESCI)
- IX. **Neoadjuvant sequential chemoradiotherapy versus radiotherapy alone for treatment of high-risk extremity soft tissue sarcoma: a single-institution experience**  
Kilic L., Ekenel M., Karabulut S., Agaoglu F., Darendeliler E.  
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, vol.21, no.1, pp.60-65, 2017 (ESCI)
- X. **Clinical significance of serum omentin-1 levels in patients with pancreatic adenocarcinoma**  
Karabulut S., Afsar C. U., Karabulut M., Alis H., Bozkurt M. A., Aydogan F., Serilmez M., Tas F.  
BBA CLINICAL, vol.6, pp.138-142, 2016 (ESCI)
- XI. **Benefit of Bevacuzimab Based Frontline Therapy in Patients with Metastatic Colorectal Cancer mCRC a Turkish Oncology Group Study**  
ARTAÇ M., COŞKUN H. Ş., DANE F., KARABULUT B., KORKMAZ L., KARAAĞAÇ M., ÇABUK D., KARABULUT S., AYKAN N. F., DORUK H., et al.  
JOURNAL OF GASTROINTESTINAL CANCER, vol.47, no.3, pp.264-272, 2016 (Scopus)
- XII. **Clinical significance of serum laminin and type-IV collagen levels in cutaneous melanoma patients**  
Tas F., Bilgin E., Karabulut S., Duranyıldız D.  
MOLECULAR AND CLINICAL ONCOLOGY, vol.5, no.1, pp.195-200, 2016 (ESCI)
- XIII. **Clinical significance of serum Protease-Activated Receptor-1 (PAR-1) levels in patients with cutaneous melanoma**  
Tas F., Bilgin E., Karabulut S., Erturk K., Duranyıldız D.  
BBA CLINICAL, vol.5, pp.166-169, 2016 (ESCI)
- XIV. **Clinical significance of serum protease-activated receptor-1 levels in gastric cancer patients**  
Tas F., Karabulut S., Tastekin D., Duranyıldız D.  
BIOMEDICAL REPORTS, vol.4, no.4, pp.489-492, 2016 (ESCI)



- XV. **Levels of serum fibronectin as a biomarker in gastric cancer patients: Correlation with clinical diagnosis and outcome**  
Tas F., Bilgin E., Karabulut S., Tastekin D., Duranyıldız D.  
MOLECULAR AND CLINICAL ONCOLOGY, vol.4, no.4, pp.655-659, 2016 (ESCI)
- XVI. **Pankreas adenokarsinomlu hastalarda serum transforme edici büyüme factor beta 1 TGF B1 düzeyleri**  
KARABULUT S., KARABULUT M., AFŞAR USUL Ç., ALIŞ H., DAĞOĞLU N., AKARSU C., ERTÜRK K., BİLGİN E., TAŞ F.  
İstanbul Tıp Fakültesi Dergisi, vol.79, no.1, pp.9-15, 2016 (Peer-Reviewed Journal)
- XVII. **Evaluation of Serum Interleukin-17 (IL-17) Levels as a Diagnostic Marker in Pancreatic Adenocarcinoma**  
KARABULUT S., Afsar Ç. U., Karabulut M., Alış H., Kılıç L., Çikot M., Yasasever C., Aykan N. F.  
Journal of Gastrointestinal Cancer, vol.47, no.1, pp.47-54, 2016 (Scopus)
- XVIII. **Is serum tenascin-C level potential biomarker in pancreatic adenocarcinoma?**  
Karabulut S., KARABULUT M., ALIS H., Tambas M., KAPAN S., KONES O., Karaman S., Serilmez M., Tas F.  
MEDICAL JOURNAL OF BAKIRKOY, vol.12, no.2, pp.76-82, 2016 (ESCI)
- XIX. **The predictive and prognostic value evaluation of serum extracellular matrix proteins levels in patients with pancreas adenocarcinoma**  
Karabulut S., KARABULUT M., ALIS H., Dagoglu N., Tambas M., KAPAN S., ORAN E., Oguz H., Tas F.  
MEDICAL JOURNAL OF BAKIRKOY, vol.12, no.1, pp.24-32, 2016 (ESCI)
- XX. **SERUM TRANSFORMING GROWTH FACTOR BETA 1 (TGF-B1) LEVELS IN PANCREATIC ADENOCARCINOMA PATIENTS**  
Karabulut S., Karabulut M., Usul Afsar C., Alis H., Dagoglu N., Akarsu C., Erturk K., Bilgin E., Tas F.  
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGİSİ, vol.79, no.1, pp.9-15, 2016 (ESCI)
- XXI. **Neoadjuvant sequential chemoradiotherapy versus radiotherapy alone for treatment of high risk extremity soft tissue sarcoma A single institution experience**  
KILIÇ L., EKENEL M., KARABULUT S., AĞAOĞLU F., DARENDELİLER M. E.  
WSPOLCZESNA ONKOLOGIA, 2016 (Scopus)
- XXII. **PANKREATİK ADENOKANSERDE SİRKÜLASYONDAKİ PROİNFLAMATUAR SİTOKİN DÜZEYLERİNİN KLİNİK ÖNEMİ**  
KARABULUT S., KARABULUT M., USUL AFŞAR Ç., Alış H., GÜVELİ M. E., Ünsal M. G., Aydoğan F., Bilgin E., BİLGİN DOĞRU E.  
İSTANBUL TIP FAKÜLTESİ DERGİSİ, vol.78, no.4, pp.102-109, 2015 (Peer-Reviewed Journal)
- XXIII. **Clinical significance of serum claudin-1 and claudin-7 levels in patients with colorectal cancer**  
Karabulut M., Alis H., Bas K., Karabulut S., Afsar C. U., Oguz H., Gunaldi M., Akarsu C., Kones O., Ayican N. F.  
MOLECULAR AND CLINICAL ONCOLOGY, vol.3, no.6, pp.1255-1267, 2015 (ESCI)
- XXIV. **To investigate possible etiologic factors of organic and functional dyspepsia in Turkey**  
KARABULUT S., Karabulut M., Akarsu C., Bozkurt M. A., BADEMLER S., Kocatas A., Basat S., Alis H.  
MEDICAL JOURNAL OF BAKIRKOY, vol.11, no.1, pp.17-23, 2015 (ESCI)
- XXV. **Sunitinib ile tedavi edilen metastatik böbrek hücreli karsinom hastalarının klinik olarak değerlendirilmesi: Tek merkez deneyimi**  
KARABULUT S., EKENEL M., IRIBAS A., DARENDELİLER E., BAŞARAN M., BAVBEK S. E.  
TÜRK ONKOLOJİ DERGİSİ, vol.30, pp.51-60, 2015 (Scopus)
- XXVI. **CLINICAL SIGNIFICANCE OF CIRCULATING PROINFLAMMATORY CYTOKINE LEVELS IN PATIENTS WITH PANCREATIC ADENOCARCINOMA**  
Karabulut S., Karabulut M., Afsar C. U., Alis H., Guveli M. E., Unsal M. G., Aydogan F., Bilgin E., Tas F.  
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGİSİ, vol.78, no.4, pp.102-109, 2015 (ESCI)
- XXVII. **Türk toplumunda organik ve fonksiyonel dispepsili hastalarda etyolojiye yönelik analiz.**  
KARABULUT S., KARABULUT M., AKARSU C., BOZKURT M. A., BADEMLER S., KOCATAŞ A., BASAT S., ALIŞ H., ALIŞ H.  
BAKIRKÖY TIP DERGİSİ, no.11, pp.17-23, 2015 (Scopus)

- XXVIII. **Clinical evaluation of sunitinib in patients with metastatic renal cell carcinoma: Single center experience**  
Karabulut S., Ekenel M., Iribas A., Darendeliler E., Basaran M., Bevbek S.  
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.30, no.2, pp.51-60, 2015 (ESCI)
- XXIX. **Endometrium Kanserinde Kemoterapi**  
KARABULUT S., SAİP P. M.  
Türkiye Klinikleri Jinekoloji Obstetrik, vol.7, no.3, pp.100-106, 2014 (Peer-Reviewed Journal)
- XXX. **The clinical effect of a positive surgical margin and adjuvant postoperative radiotherapy in the treatment of resectable desmoid tumors.**  
KARABULUT S., KESKİN S., EKENEL M., BAŞARAN M., AĞAOĞLU F., ÖZGER H., BAVBEK S.  
MOLECULAR AND CLINICAL ONCOLOGY, vol.1, pp.1061-1064, 2013 (ESCI)
- XXXI. **The Frequencies of Breast Cancer BC in Extreme Ages Changing Over Time**  
KESKİN S., ÇİFTÇİ R., KARABULUT S., KÜÇÜK S., YILDIZ İ., KILIÇ L., ERALP Y., SAİP P. M.  
Mediterranean Oncology Journal, vol.1, pp.46-19, 2012 (Peer-Reviewed Journal)

## Books & Book Chapters

- I. **Kanser Gelişen Fankoni Anemi Hastalarında Kemoterapi Modifikasyonları**  
Karabulut S., Ferhatoğlu F.  
in: Türkiye Klinikleri Çocuk Hematolojisi ve Onkolojisi, YALMAN N., Editor, Türkiye Klinikleri Yayınevi, İstanbul, pp.121-126, 2021
- II. **Kanserde Tanı ve Tedavi,**  
Sarı M., Karabulut S.  
in: Onkoloji Hemşireliği Kitabı, GÜLBELAY CAN, Editor, Nobel Tıp Kitapevi, İstanbul, pp.189-193, 2019

## Refereed Congress / Symposium Publications in Proceedings

- I. **Kolorektal Kanser Tanılı Hastalarda Sağkalımı Öngörmede Florodeoksiglukoz Pozitron Emisyon Tomografi/Bilgisayarlı Tomografi ve Serum Karsinoembriyojenik Antijen Değerinin Rolü**  
OFLAS M., HAS ŞİMŞEK D., IŞIK E. G., KIRAN M. Y., DOĞAN İ., KARABULUT S., ÖZKAN Z. G., ŞANLI Y.  
32. ULUSAL NÜKLEER TIP KONGRESİ, Turkey, 20 - 21 November 2020, vol.6, pp.16-17
- II. **Comparison of serum NEDD 9, CA 15-3 and CEA levels and PET metabolic parameters in breast cancer patients with 18 F-FDG PET / CT**  
Arslan E., Aral H., Aksoy T., Afsar C. U., Karabulut S., Trabulus F. C., Gursu R., Cermik T.  
SNMMI Annual Meeting, ELECTR NETWORK, 11 - 14 July 2020, vol.61
- III. **Does nutritional status affect treatment tolerability, response, and survival in metastatic colorectal cancer patients? Results of prospective multicenter study**  
Karabulut S., Dogan I., Afsar C. U., Karabulut M., Karaman S., Ferhatoğlu F., Tastekin D.  
Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology, San-Francisco, Costa Rica, 23 - 25 January 2020, vol.38
- IV. **Short-term outcomes of non-operative management in locally advanced distal rectal cancer patients after consolidation FOLFOX chemoradiotherapy: single center experience**  
Kulle C. B., Özgür I., Keskin M., Karaman Ş., Karabulut S., Dağoğlu Kartal M. G., Bulut M. T.  
ESCP Vienna 2019, 14th Scientific and Annual Meeting, 25-27 September 2019 Vienna, Austria, Vienna, Austria, 25 - 27 September 2019, vol.21, no.3, pp.33-128
- V. **Bipolar Hastalarda Nöroinflamasyon ve Nöronal Yıkım Belirteçlerinin Farklı Hastalık Alt Gruplarında Karşılaştırmalı İncelenmesi**  
Akcan U., Karabulut S., KÜÇÜKALİ C. İ., Çakır S., Tüzün E.  
15. Ulusal Sinirbilim Kongresi, Sakarya, Turkey, 7 - 10 May 2017

- VI. **Inflammation and neurodegeneration findings in early stage bipolar disorder**  
Karabulut S., Akcan U., KÜÇÜKALİ C. İ., Tüzün E., Çakır S.  
25th European Congress of Psychiatry, Floransa, Italy, 1 - 04 April 2017, vol.41, no.1
- VII. **Frequency of Large Deletions and Duplications in the BRCA1/2 Genes in Turkish High Risk Breast and Ovarian Cancer Cases**  
AKDENİZ ÖDEMİŞ D., ŞÜKRÜOĞLU ERDOĞAN Ö., KILIÇ S., TUNÇER Ş. B., AVŞAR M., KURU G., ALTUNDAĞ K., KILIÇ L., ÇİFTÇİ R., KARABULUT S., et al.  
International Breastanbul Conference, İstanbul, Turkey, 10 - 12 November 2016, pp.7
- VIII. **Circulating interleukin-18 (IL-18) as a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma.**  
Afsar C. U., Karabulut M., KARABULUT S., Tuna S., Alis H., Gonenc M., Dagoglu N., Bilgin E., TAŞ F.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34
- IX. **Diagnostic and prognostic roles of serum interleukin-32 (IL-32) levels in patients with pancreatic adenocarcinoma.**  
KARABULUT S., Afsar C. U., Yasasever V., Karabulut M., Erturk K., Alis H., Gunaldi M., Peker K. D., Dagoglu N., TAŞ F.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34
- X. **Metastatik hormona dirençli prostat kanserinde abirateron deneyimiz**  
KARABULUT S., EKENEL M., ÇİFTÇİ R., ÇELEBİ K., İRİBAŞ A., DARENDELİLER M. E., BAŞARAN M.  
Avrasya Üronkoloji Bahar Kongresi, Bursa, Turkey, 28 April - 01 May 2016
- XI. **Birinci basamak bevasizumab bazlı tedaviler kullanan metastatic kolorektal kanserli hastalarda primer tümörün rezeksiyonunun prognostic önemi Türk Onkoloji Grubu Çalışması**  
KORKMAZ L., COŞKUN H. Ş., DANE F., KARABULUT B., KARAAĞAÇ M., ÇABUK D., KARABULUT S., AYKAN N. F., DORUK H., AVCI N., et al.  
6. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 23 - 27 March 2016
- XII. **Do serum nectin-2 levels have a prognostic effect in patients with colorectal cancer?**  
Basaran M., KARABULUT S., KARABULUT M., GUNALDI M., ALIS H., Erturk K., Vatanserver S., Sakar B., Aykan N. F.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XIII. **Prognostic roles of serum NEDD9 levels in patients with gastric cancer.**  
Karabulut S., Karabulut M., Alis H., Bozbey H. U., Sakar B., Vatanserver S., Aykan N. F.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XIV. **Clinical significance of serum claudin-7 levels in patients with colorectal cancer.**  
Aydoğan F., Karabulut M., Alis H., Karabulut S., Celebi K., Bozbey H. U., Erturk K., Vatanserver S., Aykan N. F.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XV. **Metastatik kastrasyona dirençli prostat kanserinde abirateron deneyimimiz**  
EKENEL M., ÇİFTÇİ R., KARABULUT S., ÇELEBİ K., İRİBAS A., DARENDELİLER E., BAVBEK S., BAŞARAN M.  
21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.552
- XVI. **Trombozu olan metastatik böbrek hücreli tümörlerde sunitinib tedavisinin sonuçları**  
EKENEL M., KARABULUT S., İRİBAS A., DARENDELİLER E., BAVBEK S., BAŞARAN M.  
21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.552
- XVII. **Kolorektal Kanser Tespitinde Serum İnterlökin-17 (IL-17) Seviyelerinin Diagnostik Değeri Var Mıdır?**  
ERTÜRK K., KARABULUT M., ALIS H., GÜNALDI M., KARABULUT S., ÇELEBİ K., BOZBEY H., OĞUZ SOYDİNÇ H., KIZIR A., VATANSEVER S., et al.  
21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.1

- XVIII. **Serum NEDD9 Seviyeleri Gastrik Kanserli Hastalarda Prognostik Rolü**  
GÜNALDI M., KARABULUT M., ALIS H., KARABULUT S., KIZIR A., OĞUZ SOYDİNÇ H., VATANSEVER S., AYKAN N. F.  
21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.1
- XIX. **Metastatik böbrek hücreli tümörlerde sunitinib sonrası everolimus etkinliği**  
EKENEL M., KARABULUT S., IRIBAS A., DARENDELİLER E., BAVBEK S., BAŞARAN M.  
21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.553
- XX. **Sunitinib ile tedavi edilen metastatik renal hücreli karsinom (MRHK) hasta sonuçları, tek merkez deneyimi**  
EKENEL M., KARABULUT S., YILDIZ İ., IRIBAS A., DARENDELİLER E., BAŞARAN M., BAVBEK S.  
21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.256
- XXI. **Yüksek vücut kitle indeksi (VKİ) hedefe yönelik tedavi alan metastatik renal hücreli karsinom (BHK) hastalarında daha iyi sağkalımı öngörüyor mu?**  
KARABULUT S., EKENEL M., YILDIZ I., IRIBAS A., DARENDELİLER E., BAŞARAN M., BAVBEK S.  
21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.552
- XXII. **Kolorektal Kanserli Hastalarda Serum Epidermal Büyüme Faktör Reseptörü (EGFR) Seviyelerinin Değerlendirilmesi ve Klinikopatolojik Özelliklerle Olan Korelasyonu**  
KARABULUT S., ALIS H., KARABULUT M., GÜNALDI M., OĞUZ SOYDİNÇ H., ERTÜRK K., KAYTAN SAĞLAM E., VATANSEVER S., AYKAN N. F.  
21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015, pp.1
- XXIII. **Distribution and frequency of BRCA gene mutations in Turkish population including Balkan Turks**  
AKDENİZ D., Tuncer B. S., Kılıç S., Şükrüoğlu O., Kilic L., ALTUNDAĞ K., Ciftci R., Ozel S., Karabulut S., Ekenel M., et al.  
AACR Special Conference on Cancer Susceptibility and Cancer Susceptibility Syndromes, California, United States Of America, 29 January - 01 February 2014, vol.74
- XXIV. **The diagnostic, predictive, and prognostic role of serum cellular adhesion molecules (VCAM-1, EpCAM) levels in breast cancer patients**  
Aykan N. F., Karabulut S.  
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XXV. **Clinical significance of serum transforming growth factor beta 1 (TGFB1) level in breast cancer.**  
CIFTCI R., Tas F., Kilic L., Vatansever S., KARABULUT S.  
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XXVI. **Clinical significance of serum macrophage migration inhibitory factor (MIF) level in breast cancer.**  
CIFTCI R., Tas F., AKSIT E., Vatansever S., KARABULUT S., Sen F., YILDIZ I., Keskin S., BOZBEY H. U., Kilic L., et al.  
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XXVII. **Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in lung cancer.**  
KARABULUT S., Tastekin D., CIFTCI R., Tambas M., DAGOGLU N., Guveil M. E., Tas F., Duranyildiz D., Aydiner A.  
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XXVIII. **Clinical significance of serum caveolin-1 levels in melanoma.**  
Tastekin D., KARABULUT S., DURANYILDIZ D., Tas F.  
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XXIX. **Kalıtısal meme kanser hastalarında saptanan BRCA1 2 gen mutasyonlarının bölgesel ve etnik dağılımı ile klinik özellikleri**  
AKDENİZ ÖDEMİŞ D., TUNCER B., KILIÇ S., ŞÜKRÜOĞLU Ö., ALTUNDAĞ K., KILIÇ L., ÇİFTÇİ R., ÖZEL YILDIZ S., KARABULUT S., EKENEL M., et al.  
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014
- XXX. **Epitelyal Over Kanserinin Belirlenmesi Üzerinde Protease Activated Receptor-1 (PAR-1) Düzeylerinin**

### **Herhangi Bir Tanısal Değeri Var Mıdır?**

Karabulut S., Ciftci R., Vatanserver S., TAŞ F., TİLGEN YASASEVER C., YASASEVER F. V., Aydiner A., SAİP P. M.  
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.421

**XXXI. Epitelyal Over Kanserli Hastalarda Yüksek Serum Epidermal Büyüme Faktör Reseptörü (EGFR) Düzeyleri Kötü Progresyonsuz Sağkalımla İlişkilidir**

Karabulut S., Ciftci R., Tastekin D., TİLGEN YASASEVER C., VATANSEVER S., Duranyildiz D., TAŞ F., Aydiner A., SAİP P. M.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.428

**XXXII. Akciğer Karsinomlu Hatalarda VCAM-1 ve EPCAM Serum Konsantrasyonlarının Klinik Önemi**

Tastekin D., Karabulut S., TAŞ F., Ciftci R., TİLGEN YASASEVER C., DURANYILDIZ H. D.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.572

**XXXIII. Serum Transforme Edici Büyüme Faktörü-Beta1 (TGF-B1) Seviyelerinin Epitelyal Over Kanserli Hastalarda Klinik Önemi**

Karabulut S., Ciftci R., Tastekin D., VATANSEVER S., TAŞ F., TİLGEN YASASEVER C., DURANYILDIZ H. D., Aydiner A., SAİP P. M.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.421

**XXXIV. Meme Kanserli Hstalarda Serum MIF (Macrophage Migration Inhibitory Factor) Düzeylerinin Klinik Açıdan Önemi**

Ciftci R., Karabulut S., TİLGEN YASASEVER C., Aksit E., Yildiz I., BİLGİN DOĞRU E., Tas F., Vatanserver S., Keskin S., VATANSEVER S., et al.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.501

**XXXV. Serum Hücresel Adhezyon Molekülleri (VCAM-1, EPCAM) Seviyelerinin Meme Kanserli Hastalarda Tanısal, Prediktif ve Prognostik Rolü**

Karabulut S., Ciftci R., Tastekin D., VATANSEVER S., Aydiner A., TİLGEN YASASEVER C., Duranyildiz D., SAİP P. M.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.493

**XXXVI. Kalıtsal meme kanseri hastalarında saptanan BRCA1/2 gen mutasyonlarının bölgesel ve etnik dağılımları ile klinik özellikleri**

AKDENİZ D., TUNCER B. S., KILIC S., SUKRUOĞLU O., ALTUNDAG K., KILIÇ L., ÇİFTÇİ R., OZEL S., KARABULUT S., EKENEL M., et al.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.285

**XXXVII. Epitelya Over Kanserli Hastalarda Serum İnsulin-Like Growth Factor (IGF-1) ve İnSulin- Like Growth Factor Binding Protein-3'ün Klinik Önemi**

Tastekin D., Karabulut S., Tas F., Ciftci R., TİLGEN YASASEVER C., DURANYILDIZ H. D.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.571

**XXXVIII. Platin dirençli nüks eden baş boyun tümörlerinde setuximabın rolü, olgu değerlendirmesi**

Karabulut S., Ekenel M., Tambaş M., Taştekin D., Altun M., Meral R., Başaran M., Bavbek S.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.363

**XXXIX. Küçük hücreli dışı akciğer kanserli hastalarda anjijenik markırların prognostik ve prediktif rolü**

KESKİN S., KILIC L., YILDIZ I., ÇİFTÇİ R., KARABULUT S., ŞEN F., EKENEL M., AYDOĞAN F., TAŞ F.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 March 2014 - 23 April 2013, pp.333

**XL. Meme Kanserli Hastalarda Serum Par-1 (Protease Activated Receptor-1) Düzeylerinin Klinik Açıdan Önemi**

Ciftci R., Karabulut S., Aksit E., TAŞ F., TİLGEN YASASEVER C., VATANSEVER S., DURANYILDIZ H. D., Kilic L.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.500

**XLI. Serum Makrofaj Migrasyon İnhibitör Faktörü (MIF) Düzeylerinin Epitelyal Over Kanserli Hastalarda Tanısal, Prediktif ve Prognostik Rolü**

Karabulut S., Ciftci R., Tastekin D., Vatanserver S., Keskin S., Yildiz I., TİLGEN YASASEVER C., Duranyildiz D., Aydiner A., SAİP P. M., et al.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 19 - 23 March 2014, pp.420

**XLII. Clinical significance of serum protein and mRNA level of insulin-like growth factor-1 (IGF-1) in patients with hepatocellular carcinoma**

- Karabulut S., Aykan N. F., Yildiz I., Kilic L., Sen F., Vatansever S.  
Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 16 - 18 January 2014, vol.32
- XLIII. **Comparison of mucosal and cutaneous melanoma in the head and neck region: Different clinical features and similar outcomes.**  
Ciftci R., Keskin S., Karabulut S., Yildiz I., Kilic L., Sen F., Tastekin D., Tas F.  
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XLIV. **Coagulation assays in breast cancer: Correlation of plasma D-dimer with tumor load and invasiveness in breast cancer patients.**  
Karabulut S., Kilic L., Ciftci R., Yildiz I., Sen F., Keskin S., Tastekin D., Tas F.  
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XLV. **Rezektabl desmoid tümörlerde pozitif cerrahi sınırın ve postoperatif radyoterapinin klinik önemi**  
KARABULUT S., KESKİN S., EKENEL M., ÇİFTÇİ R., BAŞARAN M., AĞAOĞLU F., ÖZGER H., BAVBEK S.  
20. Ulusal Kanser Kongresi, Antalya, Turkey, 19 - 23 April 2013, pp.274
- XLVI. **YENİ TANI ALMIŞ MEME KANSERİ OLGULARINDA EVRELEME AMAÇLI PET-BT SONUÇLARIMIZ**  
ERTEK F., Işık E. G., Şanlı Y., Karanlık H., KESKİN S., KARABULUT S., ÖNDER S., ÜNAL S. N., MUDUN A.  
25. Ulusal Nükleer Tıp Kongresi, Antalya, Turkey, 1 - 04 April 2013, pp.53
- XLVII. **Noncutaneous melanoma have distinct features from each other and cutaneous melanoma**  
KESKİN S., EKENEL M., YILDIZ İ., KILIÇ L., KARABULUT S., ŞEN F., AYDOĞAN F., TAŞ F.  
2nd Mediterranean Multidisciplinary Oncology Forum, İstanbul, Turkey, 17 - 19 November 2011
- XLVIII. **Predictive significance of marker half life during chemotherapy in relapsed and non relapsed patients with non seminomatous germ cell testicular tumors**  
KESKİN S., EKENEL M., KARABULUT S., BAŞARAN M., BAVBEK S.  
2nd Mediterranean Multidisciplinary Oncology Forum, İstanbul, Turkey, 17 - 19 November 2011
- XLIX. **Ekzojen ghrelinin karaciğerde obestatin ve apoptotik değişiklikler üzerine etkileri**  
Karabulut S., Koyutük M., Bolkent Ş., Saçan Ö., Türk N., Yanardağ R., Bolkent S.  
XII. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Antalya, Turkey, 1 - 04 October 2011
- L. **Meme kanseri hastalarında yeniden evrelendirme amaçlı PET-BT'nin rolü**  
KUYUMCU S., KARAGÖZ F., ŞANLI Y., EKENEL M., YILDIZ İ., KARABULUT S., GEÇER F., IŞIK G., AYDINER A., SAİP P., et al.  
19. Ulusal Kanser Kongresi, Antalya, Turkey, 20 - 24 April 2011, pp.423

## **Memberships / Tasks in Scientific Organizations**

Türk Tabipler Birliği, Member, 2018 - Continues, Turkey  
American Society of Clinical Oncology (ASCO), Member, 2012 - 2018, Turkey  
European Society for Medical Oncology (ESMO), Member, 2012 - 2018, Turkey  
Türk Akciğer Kanseri Derneği, Member, 2012 - 2018, Turkey  
Türk Onkoloji Derneği, Member, 2011 - 2013, Turkey

## **Metrics**

Publication: 159  
Citation (WoS): 711  
Citation (Scopus): 775  
H-Index (WoS): 15  
H-Index (Scopus): 17

## **Non Academic Experience**

University, İstanbul Üniversitesi, Adli Tıp 3. İhtisas Kurulu